DDInter1232 DDInter178
Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix. Few other antibiotics have been discovered that work via this alkylating mechanism, making mitomycin relatively unique in the space of microbiota-derived therapies. Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper Tract Urothelial Cancer (LG-UTUC) - as well as adjunctly to _ab externo_ glaucoma surgeries.
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Mitomycin {u} (Compound) treats {v} (Disease) stomach cancer
Mitomycin {u} (Compound) binds {v} (Gene) ABCB1
Mitomycin {u} (Compound) upregulates {v} (Gene) STAP2
Mitomycin {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Mitomycin {u} (Compound) downregulates {v} (Gene) MRPL19
Mitomycin {u} (Compound) causes {v} (Side Effect) Acute respiratory distress syndrome
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gatifloxacin
Mitomycin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclophosphamide
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carmustine
Mitomycin (Compound) treats stomach cancer (Disease)
Mitomycin (Compound) binds ABCB1 (Gene)
Mitomycin (Compound) upregulates STAP2 (Gene)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class)
Mitomycin (Compound) downregulates MRPL19 (Gene)
Mitomycin (Compound) causes Acute respiratory distress syndrome (Side Effect)
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Gatifloxacin
Mitomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine